Moderna Secures EU Approval for Updated COVID Vaccine

• Moderna ( NASDAQ: MRNA ) has been approved by the European Commission for a new iteration of its COVID-19 vaccine, Spikevax.
• This new vaccination focuses on the LP.8.1 strain and is designed for people six months of age and above to assist in preventing COVID-19.
• The endorsement matches the advice of international health bodies, which recommended revising COVID-19 vaccines to target the LP.8.1 variant for the next 2025–2026 immunization period.
• This approval applies across all 27 European Union nations, as well as Iceland, Liechtenstein, and Norway.
• The doses will be available for targeted groups prior to the start of the 2025-2026 immunization period, according to the company. said .

More on Moderna

• Modern: Prepared for the Comeback Story
• Moderna, Inc. (MRNA) Participates in Barclays' "Speaking the Science" Call Series Transcripts
• Barclays: The Science of Speech Calling Series
• Modern vaccine company will reduce its workforce by 10% this year.
• Head of FDA vaccines, Chief Medical Officer Vinay Prasad leaves the agency

Berbagi :